Guangzhou Innogen Pharmaceutical Group Co., Ltd. (02591) reported no change in its total authorized share capital for November 2025. The authorized share capital remained at RMB 456,819,349, comprising 420,285,370 H shares listed on the Stock Exchange and 36,533,979 unlisted shares, both with a par value of RMB 1.
The company indicated that the issued and treasury shares remained unchanged. The total issued H shares continued at 420,285,370, while unlisted shares stood at 36,533,979. No share options, warrants, convertibles, or other arrangements to issue additional shares were disclosed.
The report was submitted on 03 December 2025 by Jin Jin, Joint Company Secretary.
Comments